AstraZeneca says chronic kidney disease drug passes final stage trial with flying colours
Farxiga was reported to show “a statistically significant and clinically meaningful effect” to prevent renal function from worsening or risk of death
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 29 of 55
AstraZeneca enters multi-billion oncology collaboration with Daiichi Sankyo, gets one step closer to EU approvals
The pair will jointly develop and commercialise a candidate for non-small cell lung cancers and breast cancers
AstraZeneca, Shell, Lloyds and other banks under the microscope in busy results week
Other updates are expected from BT, GSK, Next, Ryanair and Aston Martin, plus a US Fed meeting and a busy Wall Street earnings week including Apple and Alphabet
AstraZeneca pays US$150mln milestone as COPD treatment Breztri Aerosphere gets US approval
Breztri Aerosphere, a triple-combination inhaled treatment, showed significant improvements over dual-combination therapies in the phase III KRONOS/ETHOS trials.
Impossible to tell yet which potential coronavirus vaccine will work best, analysts say
Claims that the Oxford-AstraZeneca vaccine offers “dual protection” is totally unsubstantiated
Archive
FTSE 100 closes marginally ahead as EU rescue package cheers, gold sparkles
Britain's blue-chip benchmark finished the day up around eight points, or 0.13%, at 6,268
AstraZeneca and Oxford University vaccine triggers immune response in trial
The UK has already ordered 100 million doses of the vaccine, called AZD1222
AstraZeneca receives EU approval for Lynparza to treat metastatic pancreatic cancer mutation
The treatment targets the 5-7% of patients with pancreatic cancer who have a germline BRCA mutation
Coronavirus vaccines: Oxford candidate could be ready by autumn, flu season may wreak havoc in the winter, Australia to start first clinical trials…
Thursday's main news on vaccines development to tackle the pandemic
FTSE 100 dividend looks attractive but beware the concentration risk
Just ten blue chip stocks are forecast to pay 55% of the index's forecast total for 2020
AstraZeneca to supply up to 400 million coronavirus vaccine doses to EU countries
Deliveries will begin at the end of 2020 to countries wishing to take part in the initiative
Why do vaccine trials take so long?
It can even take a decade to find a suitable formulation against a certain disease, so reaching the final phase of trials in a matter of months is "unbelievably quick", says top scientist
AstraZeneca and Gilead Sciences merger hard to square say analysts
“Gilead needs a pipeline (which AZN has) and AZN could be looking for cash, not least to cover its dividend,”
AstraZeneca cools speculation over merger with Gilead Sciences
A deal would create a business worth around US$240bn and bring together two of the companies leading the way in the fight against coronavirus.
Archive
FTSE 100 closes in red after quiet session and excitement after Friday's jobs report wears off
Britain's blue chip benchmark finished down over 11 points at 6,472 having been in positive territory earlier
AstraZeneca reaches 2bn capacity for coronavirus vaccine doses, receives more funds from Bill Gates’ organisation
The pharma giant is producing the candidate developed by Oxford University, which is to release results on the second phase of trials by next month
AstraZeneca’s target price raised by UBS but Tagrisso margin implied in stock is out of reach
Analysts confirmed the forecast of US$8bn yearly sales but US$12bn upside “is going to be tough”
AstraZeneca in triple dose of positive results on cancer candidates
The pharma giant shared news on Enhertu, Imfinzi and Tagrisso, with the latter showing impressive results on reducing the risk of death in patients with a certain type of cancer
AstraZeneca raises hope for cure for non-small cell lung-cancer after stunning trial results
Tagrisso reduced the risk of disease recurrence or death by 83%
Coronavirus: UK begins anti-malaria drug trials as busy beaches spark controversy
The latest developments on the pandemic around the world